As of 2026-03-19, the EV/EBITDA ratio of Regenxbio Inc (RGNX) is -3.95. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RGNX's latest enterprise value is 575.73 mil USD. RGNX's TTM EBITDA according to its financial statements is -145.58 mil USD. Dividing these 2 quantities gives us the above RGNX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 19.1x | 16.0x |
| Forward P/E multiples | 19.1x - 25.5x | 21.3x |
| Fair Price | (58.06) - (57.83) | (56.72) |
| Upside | -794.5% - -791.7% | -778.5% |
| Date | EV/EBITDA |
| 2026-03-18 | -3.92 |
| 2026-03-17 | -4.05 |
| 2026-03-16 | -4.10 |
| 2026-03-13 | -4.03 |
| 2026-03-12 | -4.21 |
| 2026-03-11 | -4.31 |
| 2026-03-10 | -4.49 |
| 2026-03-09 | -4.66 |
| 2026-03-06 | -4.06 |
| 2026-03-05 | -4.08 |
| 2026-03-04 | -4.23 |
| 2026-03-03 | -4.07 |
| 2026-03-02 | -4.26 |
| 2026-02-27 | -4.19 |
| 2026-02-26 | -4.09 |
| 2026-02-25 | -4.01 |
| 2026-02-24 | -3.86 |
| 2026-02-23 | -3.81 |
| 2026-02-20 | -3.88 |
| 2026-02-19 | -3.97 |
| 2026-02-18 | -3.79 |
| 2026-02-17 | -3.84 |
| 2026-02-13 | -3.83 |
| 2026-02-12 | -3.95 |
| 2026-02-11 | -4.00 |
| 2026-02-10 | -4.13 |
| 2026-02-09 | -4.63 |
| 2026-02-06 | -4.64 |
| 2026-02-05 | -4.62 |
| 2026-02-04 | -4.79 |
| 2026-02-03 | -4.82 |
| 2026-02-02 | -4.80 |
| 2026-01-30 | -4.93 |
| 2026-01-29 | -5.08 |
| 2026-01-28 | -4.88 |
| 2026-01-27 | -5.71 |
| 2026-01-26 | -5.87 |
| 2026-01-23 | -5.84 |
| 2026-01-22 | -6.60 |
| 2026-01-21 | -6.27 |
| 2026-01-20 | -5.95 |
| 2026-01-16 | -5.78 |
| 2026-01-15 | -5.83 |
| 2026-01-14 | -6.25 |
| 2026-01-13 | -6.28 |
| 2026-01-12 | -6.29 |
| 2026-01-09 | -6.12 |
| 2026-01-08 | -6.26 |
| 2026-01-07 | -6.35 |
| 2026-01-06 | -5.98 |